BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 15908645)

  • 1. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer.
    Grothey A; Sargent DJ
    J Clin Oncol; 2005 May; 23(15):3311-3. PubMed ID: 15908645
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adjuvant therapy for colon cancer].
    Lordick F; Rosenberg R; Stein HJ; Peschel C; Siewert JR
    Dtsch Med Wochenschr; 2004 Oct; 129(44):2366-71. PubMed ID: 15497107
    [No Abstract]   [Full Text] [Related]  

  • 3. Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves C
    Nat Clin Pract Oncol; 2008 Feb; 5(2):72-3. PubMed ID: 18030299
    [No Abstract]   [Full Text] [Related]  

  • 4. Oxaliplatin (Eloxatin) for advanced colon cancer.
    Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541
    [No Abstract]   [Full Text] [Related]  

  • 5. Oxaliplatin shows significant benefit over standard therapy in early-stage colon cancer.
    Oncology (Williston Park); 2004 Sep; 18(10):1313. PubMed ID: 15526833
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant chemotherapy of colon cancer: lymph node involvement without metastases.
    Prescrire Int; 2006 Jun; 15(83):109-1. PubMed ID: 16764102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
    Krankenpfl J; 2004; 42(7-10):234. PubMed ID: 15675396
    [No Abstract]   [Full Text] [Related]  

  • 8. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial.
    Taieb J; Puig PL; Bedenne L
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):183-9. PubMed ID: 18279058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant therapy for colon cancer].
    Moiseenko VM; Orlova RV
    Vopr Onkol; 1998; 44(6):741-5. PubMed ID: 10087982
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy of colon cancer: current status and future directions.
    Chung KY; Saltz LB
    Cancer J; 2007; 13(3):192-7. PubMed ID: 17620769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
    Koperna T; Semmler D
    Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy].
    Dahlqvist C; Fremault A; Carrasco J; Colinet B
    Rev Mal Respir; 2010; 27(1):84-7. PubMed ID: 20146958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
    André T; Quinaux E; Louvet C; Colin P; Gamelin E; Bouche O; Achille E; Piedbois P; Tubiana-Mathieu N; Boutan-Laroze A; Flesch M; Lledo G; Raoul Y; Debrix I; Buyse M; de Gramont A
    J Clin Oncol; 2007 Aug; 25(24):3732-8. PubMed ID: 17704423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
    Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; Tassi R; Civitelli S; Tanzini G; Lorenzi M; Francini G
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):105-11. PubMed ID: 17429632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and challenges in the adjuvant treatment of stage II and III colon cancers.
    Chua YJ; Zalcberg JR
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):595-604. PubMed ID: 18402526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for colon cancer--what's the FUFA?
    Gupta P
    Natl Med J India; 1996; 9(4):174. PubMed ID: 8772335
    [No Abstract]   [Full Text] [Related]  

  • 19. [A case of locally advanced rectal cancer responding to FOLFOX].
    Kume S; Kubota T; Takahashi M; Hashimoto D; Hirata T; Torigoe Y; Ikeda O
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):659-61. PubMed ID: 19381043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
    Land SR; Kopec JA; Cecchini RS; Ganz PA; Wieand HS; Colangelo LH; Murphy K; Kuebler JP; Seay TE; Needles BM; Bearden JD; Colman LK; Lanier KS; Pajon ER; Cella D; Smith RE; O'Connell MJ; Costantino JP; Wolmark N
    J Clin Oncol; 2007 Jun; 25(16):2205-11. PubMed ID: 17470850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.